Inhibikase Therapeutics, Inc. (Nasdaq: IKT) announced its financial results for the year ended December 31, 2025, revealing a net loss of $48.3 million, or $0.49 per share, compared to a net loss of $27.5 million, or $1.16 per share in 2024. The company highlighted significant advancements in its clinical pipeline, particularly the transition to a global pivotal Phase 3 clinical study for its lead product candidate, IKT-001, aimed at treating Pulmonary Arterial Hypertension (PAH). CEO Mark Iwicki emphasized the importance of the fourth quarter of 2025, marking a transformational period for the company as it initiated regulatory submissions in over 20 countries and began enrolling patients in the IMPROVE-PAH study. The company also reported a cash position of $178.8 million as of December 31, 2025, a significant increase from $97.5 million in the previous year, bolstered by a $115 million public offering completed in November 2025. Inhibikase's strategic focus on advancing its clinical trials and securing regulatory approvals positions it well for future growth in the competitive biopharmaceutical landscape.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.